🎁 Black Friday: 50% off Unlimited and 30% off Pro annual plans
Ultragenyx Pharmaceutical Inc. (RARE)
NASDAQ: RARE · Real-Time Price · USD
16.48
-0.74 (-4.30%)
At close: Nov 20, 2026, 4:00 PM EST
16.50
+0.02 (0.12%)
After-hours: Nov 20, 2026, 7:31 PM EST

Ultragenyx Pharmaceutical Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
730673560434363.33351.41
Revenue Growth
15.75%20.18%29.03%19.45%3.39%29.66%
Cost of Revenue
808859775693734.11513.16
Gross Profit
-78-186-215-259-370.78-161.76
Selling, General & Admin
359349321310278.14219.98
Operating Expenses
359349321310278.14219.98
Operating Income
-437-535-536-569-648.92-381.74
Interest Expense
-83-62-63-66-43.02-29.42
Interest & Investment Income
2025372711.071.93
Currency Exchange Gain (Loss)
1-----
Other Non Operating Income (Expenses)
-11-5-1-1.57-1.69
EBT Excluding Unusual Items
-500-571-567-609-682.43-410.92
Merger & Restructuring Charges
-30-----
Gain (Loss) on Sale of Investments
-----19.3-42.06
Pretax Income
-530-571-567-609-701.73-452.98
Income Tax Expense
-642-25.71.04
Net Income
-524-575-569-607-707.42-454.03
Net Income to Common
-524-575-569-607-707.42-454.03
Net Income Growth
------
Shares Outstanding (Basic)
1019991747068
Shares Outstanding (Diluted)
1019991747068
Shares Change
3.70%8.95%23.13%5.13%3.13%11.42%
EPS (Basic)
-5.18-5.83-6.29-8.26-10.12-6.70
EPS (Diluted)
-5.18-5.83-6.29-8.26-10.12-6.70
EPS Growth
------

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
-442-472-421-519-496.59-411.79
Free Cash Flow Per Share
-4.37-4.79-4.65-7.06-7.10-6.07
Gross Margin
-10.69%-27.64%-38.39%-59.68%-102.05%-46.03%
Operating Margin
-59.86%-79.50%-95.71%-131.11%-178.60%-108.63%
Profit Margin
-71.78%-85.44%-101.61%-139.86%-194.70%-129.20%
Free Cash Flow Margin
-60.55%-70.13%-75.18%-119.59%-136.68%-117.18%
EBITDA
-403-500-500-543-630.7-368.5
EBITDA Margin
-55.21%-74.29%-89.29%-125.11%-173.59%-104.86%
D&A For EBITDA
3435362618.2213.24
EBIT
-437-535-536-569-648.92-381.74
EBIT Margin
-59.86%-79.50%-95.71%-131.11%-178.60%-108.63%
Revenue as Reported
730673560434363.33351.41
SEC Filings: 10-K · 10-Q